Download PDF
Semin Reprod Med 2016; 34(05): 299-304
DOI: 10.1055/s-0036-1592070
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Vaccine Development for Zika Virus—Timelines and Strategies

Anna P. Durbin
1   Department of International Health, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
› Author Affiliations
Further Information

Publication History

Publication Date:
08 September 2016 (online)

   Permissions and Reprints

Abstract

Zika virus is a mosquito-borne Flavivirus that spread rapidly through South and Central America in 2015 to 2016. Microcephaly has been causally associated with Zika virus infection during pregnancy and the World Health Organization declared Zika virus as a Public Health Emergency of International Concern. To address this crisis, many groups have expressed their commitment to developing a Zika virus vaccine. Different strategies for Zika virus vaccine development are being considered including recombinant live attenuated vaccines, purified inactivated vaccines (PIVs), DNA vaccines, and viral vectored vaccines. Important to Zika virus vaccine development will be the target group chosen for vaccination and which end point(s) is chosen for efficacy determination. The first clinical trials of Zika virus vaccine candidates will begin in Q3/4 2016 but the pathway to licensure for a Zika virus vaccine is expected to take several years. Efforts are ongoing to accelerate Zika virus vaccine development and evaluation with the ultimate goal of reducing time to licensure.

Keywords

Zika virus - vaccines - DNA vaccine
 

  • References

  • 1 Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 1952; 46 (5) 509-520
    CrossrefPubMedGoogle Scholar
  • 2 Hayes EB. Zika virus outside Africa. Emerg Infect Dis 2009; 15 (9) 1347-1350
    CrossrefPubMedGoogle Scholar
  • 3 Duffy MR, Chen TH, Hancock WT , et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 2009; 360 (24) 2536-2543
    CrossrefPubMedGoogle Scholar
  • 4 Cao-Lormeau VM, Roche C, Teissier A , et al. Zika virus, French Polynesia, South Pacific, 2013. Emerg Infect Dis 2014; 20 (6) 1085-1086
    PubMedGoogle Scholar
  • 5 Musso D, Nilles EJ, Cao-Lormeau VM. Rapid spread of emerging Zika virus in the Pacific area. Clin Microbiol Infect 2014; 20 (10) O595-O596
    CrossrefPubMedGoogle Scholar
  • 6 Besnard M, Lastere S, Teissier A, Cao-Lormeau V, Musso D. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. Euro Surveill 2014; 19 (13)
    PubMedGoogle Scholar
  • 7 Oehler E, Watrin L, Larre P , et al. Zika virus infection complicated by Guillain-Barre syndrome—case report, French Polynesia, December 2013. Euro Surveill 2014; 19 (9)
    PubMedGoogle Scholar
  • 8 Cauchemez S, Besnard M, Bompard P , et al. Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. Lancet 2016; 387 (10033) 2125-2132
    CrossrefPubMedGoogle Scholar
  • 9 Cao-Lormeau V-M, Blake A, Mons S , et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 2016; 387 (10027) 1531-1539
    CrossrefPubMedGoogle Scholar
  • 10 Schuler-Faccini L, Ribeiro EM, Feitosa IM , et al; Brazilian Medical Genetics Society–Zika Embryopathy Task Force. Possible association between Zika virus infection and microcephaly - Brazil, 2015. MMWR Morb Mortal Wkly Rep 2016; 65 (3) 59-62
    CrossrefPubMedGoogle Scholar
  • 11 Mlakar J, Korva M, Tul N , et al. Zika virus associated with microcephaly. N Engl J Med 2016; 374 (10) 951-958
    CrossrefPubMedGoogle Scholar
  • 12 Brasil P, Pereira Jr JP, Raja Gabaglia C , et al. Zika virus infection in pregnant women in Rio de Janeiro - preliminary report. N Engl J Med 2016; doi 10.1056/NEJMoa1602412
    PubMedGoogle Scholar
  • 13 Kleber de Oliveira W, Cortez-Escalante J, De Oliveira WT , et al. Increase in reported prevalence of microcephaly in infants born to women living in areas with confirmed Zika virus transmission during the first trimester of pregnancy - Brazil, 2015. MMWR Morb Mortal Wkly Rep 2016; 65 (9) 242-247
    CrossrefPubMedGoogle Scholar
  • 14 Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects—reviewing the evidence for causality. N Engl J Med 2016; 374 (20) 1981-1987
    CrossrefPubMedGoogle Scholar
  • 15 Pacheco O, Beltrán M, Nelson CA , et al. Zika virus disease in Colombia - preliminary report. N Engl J Med 2016; doi 10.1056/NEJMoa1604037
    PubMedGoogle Scholar
  • 16 Oster AM, Brooks JT, Stryker JE , et al. Interim guidelines for prevention of sexual transmission of Zika virus - United States, 2016. MMWR Morb Mortal Wkly Rep 2016; 65 (5) 120-121
    CrossrefPubMedGoogle Scholar
  • 17 Hills SL, Russell K, Hennessey M , et al. Transmission of Zika virus through sexual contact with travelers to areas of ongoing transmission - continental United States, 2016. MMWR Morb Mortal Wkly Rep 2016; 65 (8) 215-216
    CrossrefPubMedGoogle Scholar
  • 18 Oster AM, Russell K, Stryker JE , et al. Update: interim guidance for prevention of sexual transmission of Zika virus - United States, 2016. MMWR Morb Mortal Wkly Rep 2016; 65 (12) 323-325
    CrossrefPubMedGoogle Scholar
  • 19 Foy BD, Kobylinski KC, Chilson Foy JL , et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg Infect Dis 2011; 17 (5) 880-882
    CrossrefPubMedGoogle Scholar
  • 20 Atkinson B, Hearn P, Afrough B , et al. Detection of Zika virus in semen. Emerg Infect Dis 2016; 22 (5) 940
    CrossrefPubMedGoogle Scholar
  • 21 Johansson MA, Mier-y-Teran-Romero L, Reefhuis J, Gilboa SM, Hills SL. Zika and the risk of microcephaly. N Engl J Med 2016; 375 (1) 1-4
    CrossrefPubMedGoogle Scholar
  • 22 WHO. WHO and experts prioritize vaccines, diagnostics, and innovative vector control tools for Zika R&D. 2016. Available at: http://www.who.int/mediacentre/news/notes/2016/research-development-zika/en/ . Accessed June 30, 2016
    PubMedGoogle Scholar
  • 23 Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977; 265 (5596) 739-741
    CrossrefPubMedGoogle Scholar
  • 24 Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989; 40 (4) 444-451
    PubMedGoogle Scholar
  • 25 Guzmán MG, Kourí G, Valdés L, Bravo J, Vázquez S, Halstead SB. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica 2002; 11 (4) 223-227
    CrossrefPubMedGoogle Scholar
  • 26 Kliks SC, Nimmanitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988; 38 (2) 411-419
    PubMedGoogle Scholar
  • 27 Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988; 38 (1) 172-180
    PubMedGoogle Scholar
  • 28 Vaughn DW, Green S, Kalayanarooj S , et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181 (1) 2-9
    CrossrefPubMedGoogle Scholar
  • 29 Fagbami AH, Halstead SB, Marchette NJ, Larsen K. Cross-infection enhancement among African flaviviruses by immune mouse ascitic fluids. Cytobios 1987; 49 (196) 49-55
    PubMedGoogle Scholar
  • 30 Dejnirattisai W, Supasa P, Wongwiwat W , et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat Immunol 2016; doi 10.1038/ni.3515
    PubMedGoogle Scholar
  • 31 Guirakhoo F, Kitchener S, Morrison D , et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006; 2 (2) 60-67
    CrossrefPubMedGoogle Scholar
  • 32 Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan G. Live-attenuated tetravalent dengue vaccine in dengue-naïve children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 2011; 30 (1) e9-e17
    CrossrefPubMedGoogle Scholar
  • 33 Capeding RZ, Luna IA, Bomasang E , et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 2011; 29 (22) 3863-3872
    CrossrefPubMedGoogle Scholar
  • 34 Hadinegoro SR, Arredondo-García JL, Capeding MR , et al; CYD-TDV Dengue Vaccine Working Group. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015; 373 (13) 1195-1206
    CrossrefPubMedGoogle Scholar
  • 35 WHO. WHO global consultation of research related to Zika virus infection. Paper Presented at: WHO Global Consultation of Research Related to Zika Virus Infection; Geneva; March 7–9, 2016
    PubMedGoogle Scholar
  • 36 Larocca RA, Abbink P, Peron JP , et al. Vaccine protection against Zika virus from Brazil. Nature 2016; doi 10.1038/nature18952
    PubMedGoogle Scholar
  • 37 Kirkpatrick BD, Durbin AP, Pierce KK , et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, Flavivirus-naive adults. J Infect Dis 2015; 212 (5) 702-710
    CrossrefPubMedGoogle Scholar
  • 38 Kirkpatrick BD, Whitehead SS, Pierce KK , et al. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci Transl Med 2016; 8 (330) 330ra36
    CrossrefPubMedGoogle Scholar
  • 39 Ledgerwood JE, Pierson TC, Hubka SA , et al; VRC 303 Study Team. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 2011; 203 (10) 1396-1404
    CrossrefPubMedGoogle Scholar
  • 40 Dyer O. Trials of Zika vaccine are set to begin in North America. BMJ 2016; 353: i3588
    PubMedGoogle Scholar
  • 41 Thomas DL, Sharp TM, Torres J , et al. Local transmission of Zika virus—Puerto Rico, November 23, 2015-January 28, 2016. MMWR Morb Mortal Wkly Rep 2016; 65 (6) 154-158
    CrossrefPubMedGoogle Scholar
  • 42 Gourinat AC, O'Connor O, Calvez E, Goarant C, Dupont-Rouzeyrol M. Detection of Zika virus in urine. Emerg Infect Dis 2015; 21 (1) 84-86
    CrossrefPubMedGoogle Scholar
  • 43 Lanciotti RS, Kosoy OL, Laven JJ , et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis 2008; 14 (8) 1232-1239
    CrossrefPubMedGoogle Scholar